Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Allergan, eBay, Dynavax, KBR, and More Are Trending

Page 1 of 2

It’s a red day on Wall Street, as all three major indexes are off by around 0.35%, potentially due to some market participants remaining on the sidelines until the Deutsche Bank AG (USA) (NYSE:DB) uncertainty is finally settled. Although traditional wisdom says that either the U.S. government will settle for a relatively-painless amount or that the German government will bail the bank out, stranger things have happened before.

In this article, we’ll take a look at why Allergan plc Ordinary Shares (NYSE:AGN), AstraZeneca plc (ADR) (NYSE:AZN), eBay Inc (NASDAQ:EBAY), KBR, Inc. (NYSE:KBR), and Dynavax Technologies Corporation (NASDAQ:DVAX) are capturing investors’ attention this morning. In order to make a more complete analysis, we’ll also check SEC filings to see what the smart money thinks of each stock.

Through extensive research, we determined that imitating some of the picks of hedge funds and other institutional investors can help generate market-beating returns over the long run. The key is to focus on the small-cap picks of these investors, since they are usually less followed by the broader market and are less price-efficient. Our backtests that covered the period between 1999 and 2012, showed that following the 15 most popular small-caps among hedge funds can help a retail investor beat the market by an average of 95 basis points per month (see the details here).

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


Two drug companies are in the spotlight today after Allergan plc Ordinary Shares (NYSE:AGN) entered into an exclusive license agreement with AstraZeneca plc (ADR) (NYSE:AZN) to obtain the global development and commercialization rights to the latter’s MEDI2070 inflammatory disorder development program. Under the terms of the deal, Allergan will pay AstraZeneca an upfront payment of $250 million and up to $1.27 billion in potential launch and sales-based milestone disbursements over a period of up to 15 years. MEDI2070 is an anti-IL-23 monoclonal antibody in Phase IIb clinical development for the treatment of patients with moderate-to-severe Crohn’s disease. It is also Phase II ready for ulcerative colitis and other associated conditions.

Follow Allergan Inc (NYSE:AGN)
Trade (NYSE:AGN) Now!

Of the 749 hedge funds that we track which filed 13Fs for the June quarter, 131 of them were long Allergan plc Ordinary Shares (NYSE:AGN) on June 30, while 24  of them were shareholders of AstraZeneca plc (ADR) (NYSE:AZN).

Follow Astrazeneca Plc (NYSE:AZN)
Trade (NYSE:AZN) Now!

eBay Inc (NASDAQ:EBAY) shares are almost 2% in the red after Facebook Inc (NASDAQ:FB) introduced ‘Marketplace’, which is intended to allow the social media giant to compete against eBay and Craigslist in the e-commerce realm. Facebook’s Marketplace feature is a revamped, more mobile-focused version of its previous Classified/Marketplace function, and could take market share away from eBay in the long run given Facebook’s massive daily user-base and its strong engagement. Jim Simons‘ Renaissance Technologies bumped up its holding in eBay Inc (NASDAQ:EBAY) by 59% during the second quarter to just over 3 million shares as of June 30.

Follow Ebay Inc (NASDAQ:EBAY)
Trade (NASDAQ:EBAY) Now!

On the next page, we’ll find out why KBR Inc and Dynavax Technologies are heading in opposite directions this morning.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!